Emerging antibiotic resistance in Pseudomonas-A challenge

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 3, Issue 2, 2011, Pages 82-84

  Arora, Deepak ^a   Jindal, Neerja ^b   Kumar, Rajiv ^a   Romit, ^b  

^a Adesh Medical College   (India)

^b GGS Medical College & Hospital Faridkot   (India)

Author keywords

Antibiotic susceptibility; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; PIPERACILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; INDIA; MICROBIAL GENETICS; NONHUMAN; PSEUDOMONAS AERUGINOSA;

EID: 79955941999     PISSN: 09751491     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Costerton JW, et al. The Role of the microcolony mode of growth in the pathogenesis of Pseudomonas aeruginosa infections. Rev Infect Dis 1983; 5: S867-872.
2. Bennett. Principles and Practice of Infectious Diseases. Second Edition, 1985;.3.
3. Pseudomonas aeruginosa: Review of recent trends. Rev Infect Dis 1983; 5: S837-844.
4. Schimpff SC, Moody M., Young VM. Relationship of colonization with Pseudomonas aeruginosa to development of Pseudomonas aeruginosa bacteremia in cancer patients. Antimicrob Agents Chemother 1970; 240.
5. Korvick JA, Marsh JW, Starzl TE, et al. Pseudomonas aeruginosa bacteremia in patients undergoing liver transplantation: an emerging problem. Surgery 1991; 109: 62-68.
6. Griffith SJ, Nathan C, Selander RK, et al. The epidemiology of Pseudomonas aeruginosa in oncology patients in a general hospital. J Infect Dis 1989; 160: 1030-6.
7. Young LS, et al. The clinical challenge of infections due to Pseudomonas aeruginosa. Rev Infect Dis 1984; 6: 603-7.
8. Hilf M., Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. AM J Med, 1989; 87: 540-6.
9. Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. J. Antimicrob. Chemother. 29 Suppl A 1992; 19-24.
10. Trilla A, et al. Epidemiology of nosocomial infections in adult intensive care units. Intensive Care Med 20 Suppl 1994; 3: S1-4
11. Gilligan PH: Pseudomonas and Burkholderia. In Manual of Clinical Microbiology (Eds. Mur ray RR, Baron EJ, Pfaler MA, Tenover FC, Yolken RH) American Society for Microbiology, Washington DC, 1995; 509-19.
12. Trilla A, et al. Epidemiology of nosocomial infections in adult intensive care units. Intensive Care Med 20 Suppl.1994; 3: S1-4.
13. Archibald L, Phiilips L, Monnett D et al. Antimicrobial resistance in hospitals and outpatients in the United States: the increasing importance of the intensive care unit. Clin Infect Dis.1997; 24: 211-5.
14. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different anti pseudomonal agents. Antimicrob Agents Chemother. 1999; 43: 1379-82.
15. Linden PK, Kusne S, Coley K., et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobialresistant Pseudomonas aeruginosa 2003; 37: 154-60.
16. Maniatis AN, Trougakos IP, Katsanis G et al. Changing patterns of bacterial nosocomial infections: a nine-year study in a general hospital. Chemotherapy 1997; 43: 69-76.
17. Holloway wj, palmer d, clinical application of new parentral antibiotic in treatment of severe bacterial infection, Amm j med 1996; 525-595.
18. Alkin HE, Torun M, Alacam R, et al. Aminoglycoside resistance pattern in turkey scand. Journal of infect disease.1988; 20; 199-202.
19. Smitha S, Lalitha P, Prajna VN, Srinivasan M, et al. Susceptibility trends of Pseudomonas species from corneal ulcers. Indian J Med Microbiol 2005; 23: 168-71.
20. Poole K. Aminoglycosides resistance in Pseudomonas aeruginosa. Antimicrob Agents Chem 2005; 49: 479-87.
21. Hancock RE, et al. Resistance mechanism in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis. 1998; 27: 289-99.
22. Bouza E, Garcia-Gorrote F, Cercenado E, Marin M, Diaz MS, et al. Pseudomonas aeruginosa: a survey of resistance in 136 hospitals in Spain. The Spanish Pseudomonas aeruginosa Study Group. Antimicrob Agents Chemother. 1999; 43: 981-2.
23. Bonfiglio G, Carciotto V, Russo G et al. Antibiotic resistance in Pseudomonas aeruginosa: An Italian survey. Antimicrob Chemother. 1998; 41: 307-10.
24. Rotimi VO, Sweih NA, Feteih J, et al. The prevalence and antibioticsusceptibility pattern of gram-negative bacterial isolates in two ICUs in Saudi Arabia and Kuwait. Diagn Microbiol Infect Dis. 1998; 30: 53-9.
25. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1990-May 1999. Am J Infect Control 1999; 27: 520-32.
26. Pfaller MA, Jones RN. MYSTIC (Meropenem yearly susceptibility test information collection) results from the Americas: resistance implications in the treatment of serious infections. J Antimicrob Chemother. 2000; 46: 25-37.
27. Tassios PT, Gennimata V, Maniatis A et al. Emergence of multidrug resistance in ubiquitous and dominant Pseudomonas aeruginosa serogroup 0: 11. J Clin Microbiol 1998; 36: 897-901.
28. Sofianou D, Tsakris A, Skoura L, Douboyas J. Extended high level cross resistance to antipseudomonal antibiotics amongst Pseudomonas aeruginosa isolates in a university hospital. J. Antimicrob Chemother 1997; 40: 740-2.
29. Maes P, Vanhoof R. A 56-months prospective surveillance study on the epidemiology of aminoglycoside resistance in a Belgian general hospital. Scand J Infect Dis. 1992; 24: 495-501.
30. Quinn JP. Clinical problems posed by multiresistant nonfermenting gram-negative pathogens. Clin Infect Dis. 1998; 27: 117-4.